Screen for capturing tumor cells in human blood

By developing a capture screen for tumor cells in human blood in tumor diagnosis, combining physical and immunostaining methods, using nickel alloy screen and fully automatic sample loader, the early detection difficulties and trauma of tumor diagnosis in the prior art are solved. The major problems have achieved accurate capture and detection of tumor cells, provided an efficient and accurate experimental platform, and promoted the development of cancer research and clinical applications.

CN119020147APending Publication Date: 2024-11-26SUZHOU BOFU BIOMEDICAL TECH CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411238988.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-05
Publication Date
2024-11-26

AI Technical Summary

Technical Problem

The prior art has problems in the diagnosis of tumors that cannot detect small lesions in the early stage, difficulty in examining head and lung tumors, poor specificity of serological detection, and large trauma and time-consuming pathological biopsy.

Method used

Develop a capture screen for tumor cells in human blood, using physical and immunostaining methods to capture and identify tumor cells of different sizes through nickel alloy screens, and combine them with fully automatic sample loaders and fluorescence microscopes for cell counting and staining. , realize the precise capture and detection of tumor cells in the blood.

Benefits of technology

It realizes monitoring of early auxiliary diagnosis and therapeutic prognosis of tumor cells, reduces cell mechanical damage, improves the repetition and accuracy of experiments, and provides an efficient, accurate and repeatable experimental platform suitable for high-throughput experimental design , suitable for the development of early cancer diagnosis and personalized treatment plans.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119020147A_ABST
    Figure CN119020147A_ABST
Patent Text Reader

Abstract

The invention provides a capturing screen for tumor cells in human blood, and relates to the technical field of biomedical engineering.The capturing screen comprises a screen body, according to cells of different sizes, large-size cells are captured through a physical method, small-size cells are removed, and the captured cells are dyed through an immunostaining method; the screen body is made of nickel alloy, the nickel alloy has good mechanical performance and corrosion resistance, so that the screen body has long service life and stability in biological liquid such as blood, and the nickel alloy is commonly used for manufacturing implants and the like in the field of biomedicine and has good biocompatibility. Compared with the prior art, interference to blood components and immunoreaction of a patient are reduced, cleaning and disinfection are easy, repeated use of the screen body is facilitated, the risk of cross infection is reduced, the outer ring diameter of the screen body is 8.8 mm, the inner ring diameter of the screen body is 6.0 mm, and due to the design, directional capturing is facilitated, namely only cells in a specific area are captured.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the technical field of biomedical engineering, and more specifically, particularly relates to a capture screen for tumor cells in human blood. Background Art

[0002] Tumor is a genetic disease, but not hereditary. It refers to the change of genes in cells under the influence of carcinogenic factors, which leads to the loss of normal regulation of their growth, resulting in the formation of new organisms due to monoclonal abnormal proliferation. At present, the main methods for tumor detection include imaging examination, ultrasound, magnetic resonance imaging, nuclear medicine, blood test, etc. Among them, blood test is an important means to detect early cancer in physical examination. By detecting whether various tumor markers in the blood are elevated, various malignant tumors can be discovered and identified. Studies have also found that tumor cells can fall off, invade, and enter the blood circulation from solid tumors to achieve distant metastasis of tumors, which is closely related to the progression and recurrence of tumors. Therefore, the detection of tumor cells in the blood is helpful for the diagnosis of patients with tumor metastasis, monitoring the recurrence of tumors in patients after surgery, and evaluating the sensitivity of anti-tumor drugs and patient prognosis. Therefore, this study intends to develop a sieve chip that captures tumor cells in the blood according to different cell sizes, which can realize the capture and detection of tumor cells in the blood.

[0003] Currently, no matter which technology is used to diagnose tumors, there are unsolvable disadvantages:

[0004] 1. Imaging assessment is a non-invasive assessment, but it requires the tumor to reach a certain volume and have a high resolution. It is difficult to detect particularly small lesions and requires dynamic monitoring.

[0005] 2. Ultrasound mainly uses ultrasonic waves to explore the human body. It cannot be used to examine tumors in the head and lungs. The abdomen and pelvis are easily affected by intestinal gas, which makes diagnosis difficult.

[0006] 3. Serological testing, such as marker testing, but the specificity of marker testing is not strong, and not all tumor patients will have elevated markers.

[0007] 4. The main disadvantage of pathological biopsy is that it is difficult to obtain pathological specimens, such as colonoscopy specimens, puncture specimens of liver lesions, etc. Patients undergoing tumor evaluation need to take samples multiple times, which will face invasive operations, some trauma, and increase costs. In addition, the waiting time for pathological testing is long.

[0008] To this end, the present invention intends to develop a sieve chip for capturing tumor cells in the blood according to different cell sizes, which can realize the capture and detection of tumor cells in the blood, realize early auxiliary diagnosis of tumors and monitoring of treatment prognosis, in order to achieve a more practical purpose. Summary of the invention

[0009] In order to solve the above technical problems, the present invention provides a capture screen for tumor cells in human blood to solve the above problems.

[0010] A capture screen for tumor cells in human blood comprises a screen body. According to cells of different sizes, a physical method is used to capture large-sized cells and small-sized cells are removed. The captured cells are stained by immunostaining to determine whether they are tumor cells. A screen body with a pore size of 13-20 μm, a thickness of 10-30 μm, and a wire diameter of 5-10 μm is used to capture tumor cells. The capture rate of the screen body is tested using breast cancer SK-BR-3, MCF-7, and MDA-MB-231 cells. The clinical consistency of the screen body is tested using cancers such as intestinal cancer, liver cancer, breast cancer, and lung cancer. 4 mL of human peripheral blood is drawn into a coagulation tube and stored at 2-8° C. for later use.

[0011] Preferably, 4 mL of peripheral blood is transferred from the anticoagulant tube to a 15 mL centrifuge tube, 4 mL of PBS is added to dilute the blood 1:1 and mix thoroughly, 4 mL of lymphocyte separation fluid is taken into a new 15 mL centrifuge tube, and the diluted blood is transferred to the centrifuge tube.

[0012] Preferably, a horizontal centrifuge is used at room temperature, 2500rpm, and centrifuged for 20min. After centrifugation, the plasma layer is carefully aspirated vertically using a pipette, and the PBMC layer is aspirated into a 15mL centrifuge tube, and 10mL PBS is added to wash once, and centrifuged at room temperature, 1500rpm, for 5min. After centrifugation, the supernatant is discarded, and 300μL PBS is added to resuspend the PBMC for later use. The clinical samples are directly loaded onto the machine for detection.

[0013] Preferably, use a pipette to place all the cell mixture into the loading well, and use Huixian Pharmaceutical The 2000 fully automatic sampler was used to capture and stain tumor cells. After the instrument was finished running, a fluorescence microscope was used to count the captured cells and calculate the capture rate.

[0014] Compared with the prior art, the present invention has the following beneficial effects:

[0015] In the present invention, the plasma layer is carefully sucked vertically with a pipette, and then the PBMC layer is sucked into a 15mL centrifuge tube, and 10mL PBS is added to wash once, and centrifuged at room temperature 1500rpm for 5 minutes. After centrifugation, the supernatant is discarded, and 300μL PBS is added to resuspend the PBMC for standby use. The clinical sample is directly loaded on the machine for detection. The overall mechanical damage to the cells can be reduced by accurately controlling the centrifugation speed and time, and the integrity and activity of the cells can be maintained. By sucking the plasma layer, plasma proteins and other components that may interfere with subsequent experiments are removed. Density gradient centrifugation is performed using lymphocyte separation fluid to effectively separate PBMCs. These cells are very important for many immunological studies and clinical tests. The PBS washing step removes residual red blood cells, platelets and separation fluid, and reduces background noise in subsequent experiments.

[0016] In the present invention, cell counting can be performed by a microscope to accurately obtain the number of cells, provide accurate cell concentration for subsequent experiments, and adjust the cell concentration by gradient dilution to meet the requirements of cell number in different experimental steps. SK-BR-3 cells are mixed with PBMC mixed solution to simulate the environment in which tumor cells and normal cells coexist in vivo, which is helpful for studying the interaction between tumor cells and host cells. Tumor cell capture requires the use of a pipette to place all the cell mixture in the loading well, using Huixian Pharmaceutical The 2000 fully automatic sampler captures and stains tumor cells, improving the repeatability and accuracy of the experiment and reducing errors caused by human operation. After the instrument is finished running, a fluorescence microscope is used to count the captured cells. By using a fluorescence microscope to count the captured cells, the cell status can be intuitively observed and analyzed, facilitating quantitative analysis.

[0017] In the present invention, in order to provide data support for optimizing experimental conditions, the capture rate detection of the tumor cells of the present invention (taking breast cancer SK-BR-3 cells as target cells) is used, which is helpful to study the biological characteristics and metastasis mechanism of breast cancer cells. The detection results show that the capture rate of SK-BR-3 cells by this method is between 65% and 82%, and it has a good cell capture effect. The method is suitable for high-throughput experimental design and can quickly analyze a large number of samples in a short time. By studying the capture and detection of tumor cells, an experimental basis can be provided for the early diagnosis, efficacy evaluation and prognosis of cancer. By analyzing the characteristics of tumor cells of different patients, it is helpful to develop personalized treatment plans. This method provides an efficient, accurate and repeatable experimental platform for the study of tumor cells, which is helpful to promote the development of cancer research and clinical applications.

[0018] In the present invention, the material of the screen body is nickel alloy, which has good mechanical properties and corrosion resistance, which makes the screen body have a long service life and stability in biological fluids such as blood. Nickel alloy is often used in the biomedical field to manufacture implants, etc., has good biocompatibility, reduces interference with blood components and patients' immune responses, and is easy to clean and disinfect, which facilitates the reuse of the screen body and reduces the risk of cross infection. The outer ring diameter of the screen body is 8.8 mm and the inner ring diameter is 6.0 mm. This design facilitates directional capture, that is, only capturing cells in a specific area, which can be used to improve the accuracy of capturing tumor cells.

[0019] In the present invention, the thickness of the sieve body is 20 μm, which can ensure the uniformity and consistency of filtration, help capture cells of target size, and allow smaller blood cells to pass through. The sieve body of this size and design can be easily integrated into automated blood analysis equipment to achieve rapid, high-throughput tumor cell capture and analysis. The pore size of the sieve body is 18 μm, and the wire diameter of the sieve body is 8 μm. This design can provide a higher porosity, which helps to improve the filtration efficiency of the sieve body, allowing blood cells to pass through smoothly while capturing larger tumor cells. By effectively capturing tumor cells in the blood, this sieve body is helpful for early diagnosis and treatment monitoring of cancer. Compared with traditional tissue biopsy, using a sieve body to capture CTCs is a minimally invasive or non-invasive method, which is more patient-friendly, and this sieve body can not only be used for clinical diagnosis, but also play a role in cancer biology research, such as studying the heterogeneity and metastasis mechanism of tumor cells. BRIEF DESCRIPTION OF THE DRAWINGS

[0020] Figure 1 It is a schematic diagram of the overall structure of the present invention;

[0021] In the figure, the corresponding relationship between the component names and the figure numbers is: 1. Screen body. DETAILED DESCRIPTION

[0022] The following embodiments of the present invention are described in further detail in conjunction with the accompanying drawings and examples. The following examples are used to illustrate the present invention, but are not intended to limit the scope of the present invention.

[0023] See also Figure 1The present invention provides a capture screen for tumor cells in human blood, comprising a screen body 1. According to cells of different sizes, a physical method is used to capture large-sized cells, and small-sized cells are removed. The captured cells are stained by immunostaining to determine whether they are tumor cells. The screen body 1 with a pore size of 13-20 μm, a thickness of 10-30 μm, and a wire diameter of 5-10 μm is used to capture tumor cells. The screen body 1 is stained with breast cancer SK-BR-3, MCF-7, and MDA-MB-231 cells. Capture rate test, clinical consistency test of the screen body 1 using colorectal cancer, liver cancer, breast cancer, lung cancer and other cancer types, 4 mL of human peripheral blood was drawn into a coagulation tube and stored at 2-8 ° C for later use. When preparing PBMC cells and processing clinical samples, 4 mL of human peripheral blood was first drawn into a coagulation tube and stored at 2-8 ° C for later use. By storing at 2-8 ° C and processing quickly, the biological stability of the sample was maintained to avoid changes in cell state caused by temperature changes or long-term exposure. 4 mL of peripheral blood was transferred from the anticoagulation tube to a 15 mL centrifuge tube and 4 mL was added. Dilute the blood 1:1 with PBS and mix thoroughly. Take 4 mL of lymphocyte separation solution in a new 15 mL centrifuge tube, transfer the diluted blood to the centrifuge tube, use a horizontal centrifuge at room temperature, 2500 rpm, centrifuge for 20 minutes. After centrifugation, use a pipette to carefully aspirate the plasma layer vertically, then aspirate the PBMC layer into a 15 mL centrifuge tube, add 10 mL PBS to wash once, centrifuge at room temperature 1500 rpm for 5 minutes. After centrifugation, discard the supernatant, add 300 μL PBS to resuspend the PBMC for later use. Clinical samples are directly loaded on the machine for testing. The overall centrifugation speed and time can be precisely controlled to reduce mechanical damage to cells and maintain cell integrity and activity. By aspirating the plasma layer, plasma proteins and other components that may interfere with subsequent experiments are removed. Density gradient centrifugation is performed using lymphocyte separation solution to effectively separate PBMCs. These cells are very important for many immunological studies and clinical tests. The PBS washing step removes residual red blood cells, platelets and separation solution to reduce background noise in subsequent experiments.

[0024] Transfer 4 mL of peripheral blood from the anticoagulant tube to a 15 mL centrifuge tube, add 4 mL of PBS to dilute the blood 1:1 and mix thoroughly, take 4 mL of lymphocyte separation solution in a new 15 mL centrifuge tube, transfer the diluted blood to the centrifuge tube, prepare tumor cell lines, culture SK-BR-3 cells, the cell culture medium requires MEM culture medium, 10% fetal bovine serum, 1% double antibody, which provides a suitable growth environment for SK-BR-3 cells, and the culture conditions require 5% carbon dioxide. SK-BR-3 cells are cultured in a T25 cell culture flask in a 37°C incubator. The culture conditions of 5% carbon dioxide and 37°C simulate the environment in the human body, which is conducive to the normal growth of cells and the maintenance of their characteristics. Cell counting, after gradient dilution, use a microscope to count SK-BR-3 cells, and place 30-70 SK-BR-3 cells in step 4.3.1 300 μL In the PBMC mixture, cell counting can be performed with a microscope to accurately obtain the number of cells and provide accurate cell concentration for subsequent experiments. The cell concentration can be adjusted by gradient dilution to meet the requirements of cell number in different experimental steps. Mixing SK-BR-3 cells with the PBMC mixture simulates the environment in which tumor cells and normal cells coexist in the body, which is helpful for studying the interaction between tumor cells and host cells. Tumor cell capture requires the use of a pipette to place all the cell mixture in the loading well. The 2000 fully automatic sampler is used to capture and stain tumor cells, which improves the repeatability and accuracy of the experiment and reduces the error of human operation. After the instrument is finished running, the captured cells are counted using a fluorescence microscope. By using a fluorescence microscope to count the captured cells, the cell state can be intuitively observed and analyzed, which is convenient for quantitative analysis and calculation of the capture rate. The effectiveness of the capture method can be evaluated, and data support can be provided for optimizing experimental conditions. The capture rate detection of the tumor cells of the present invention (taking breast cancer SK-BR-3 cells as the target cells) is helpful for studying the biological characteristics and metastasis mechanism of breast cancer cells. The test results show that the capture rate of SK-BR-3 cells by this method is between 65% and 82%, and it has a good cell capture effect. The above steps constitute a complete experimental process, from cell culture to capture The capture rate detection ensures the systematicness and integrity of the experiment. The method is suitable for high-throughput experimental design and can quickly analyze a large number of samples in a short time. By studying the capture and detection of tumor cells, it can provide experimental basis for early diagnosis, efficacy evaluation and prognosis of cancer. By analyzing the characteristics of tumor cells from different patients, it is helpful to develop personalized treatment plans. This method provides an efficient, accurate and repeatable experimental platform for tumor cell research, which helps to promote the development of cancer research and clinical applications. At the same time, the sieve body 1 was used to detect tumor cells in the blood of ten samples. The test results showed that the consistency between the tumor cell detection results and the clinical diagnosis results was 90%. Therefore, the invention can detect tumor cells in the blood, thereby providing tumor patients with a low-invasive, low-cost, fast and accurate detection method.

[0025] Use a horizontal centrifuge at room temperature, 2500rpm, centrifuge for 20min. After centrifugation, use a pipette to carefully aspirate the plasma layer vertically, aspirate the PBMC layer into a 15mL centrifuge tube, and add 10mL PBS to wash once, centrifuge at room temperature 1500rpm for 5min. After centrifugation, discard the supernatant, add 300μL PBS to resuspend the PBMC for later use, and directly load the clinical sample on the machine for testing. The screen body 1 is made of nickel alloy, which has good mechanical properties and corrosion resistance, which makes the screen body 1 have a long service life and stability in biological fluids such as blood. Nickel alloy is often used in the biomedical field to manufacture implants, etc., with good biocompatibility, reducing interference with blood components and patients' immune responses, and is easy to clean and disinfect, which helps to reuse the screen body 1 and reduce the risk of cross infection. The outer ring diameter of the screen body 1 is 8.8mm and the inner ring diameter is 6.0mm. This design helps to capture directional, that is, only capture cells in a specific area, which can be used to improve the accuracy of capturing tumor cells.

[0026] Use a pipette to place all the cell mixture into the sample wells and use Huixian Pharmaceutical The 2000 fully automatic sampler is used to capture and stain tumor cells. After the instrument is finished running, the captured cells are counted using a fluorescent microscope and the capture rate is calculated. The thickness of the mesh body 1 is 20μm, which can ensure the uniformity and consistency of filtration, help capture cells of the target size, and allow smaller blood cells to pass through. The mesh body 1 of this size and design can be easily integrated into automated blood analysis equipment to achieve rapid and high-throughput tumor cell capture and analysis. The pore size of the mesh body 1 is 18μm, and the wire diameter of the mesh body 1 is 8μm. This design can provide a higher porosity, which helps to improve the filtration efficiency of the mesh body 1, allowing blood cells to pass smoothly while capturing larger tumor cells. By effectively capturing tumor cells in the blood, this mesh body 1 contributes to the early diagnosis and treatment monitoring of cancer. Compared with traditional tissue biopsy, using the mesh body 1 to capture CTCs is a minimally invasive or non-invasive method that is more patient-friendly, and this mesh body 1 can not only be used for clinical diagnosis, but also play a role in cancer biology research, such as studying the heterogeneity and metastasis mechanism of tumor cells.

[0027] Working principle:

[0028] In the first step, when preparing PBMC cells and processing clinical samples, first draw 4 mL of human peripheral blood into a coagulation tube and store it at 2-8°C for use. By storing it at 2-8°C and processing it quickly, the biological stability of the sample is maintained to avoid changes in cell state caused by temperature changes or long-term exposure. Transfer 4 mL of peripheral blood from the anticoagulation tube to a 15 mL centrifuge tube, add 4 mL of PBS to dilute the blood 1:1 and mix it thoroughly, take 4 mL of lymphocyte separation fluid into a new 15 mL centrifuge tube, transfer the diluted blood to the centrifuge tube, use a horizontal centrifuge at room temperature, 2500 rpm, centrifuge for 20 minutes, after the centrifugation, use a pipette to carefully aspirate the plasma layer vertically, then aspirate the PBMC layer into a 15 mL centrifuge tube, add 10 mL of PBS to wash once, centrifuge at room temperature 1500 rpm for 5 minutes, after centrifugation, discard the supernatant, and add 300 μL PBMCs are resuspended in PBS for later use, and clinical samples are directly loaded onto the machine for testing. The centrifugation speed and time can be precisely controlled to reduce mechanical damage to cells and maintain cell integrity and activity. The plasma layer is aspirated to remove plasma proteins and other components that may interfere with subsequent experiments. Density gradient centrifugation is performed using lymphocyte separation fluid to effectively separate PBMCs, which are very important for many immunological studies and clinical tests. The PBS washing step removes residual red blood cells, platelets, and separation fluid to reduce background noise in subsequent experiments.

[0029] The second step is to prepare the tumor cell line and culture SK-BR-3 cells. The cell culture medium needs MEM culture medium, 10% fetal bovine serum, and 1% double antibody, which provides a suitable growth environment for SK-BR-3 cells. The culture conditions require 5% carbon dioxide. SK-BR-3 cells are cultured in T25 cell culture bottles in a 37°C incubator. The culture conditions of 5% carbon dioxide and 37°C simulate the environment in the human body, which is conducive to the normal growth of cells and the maintenance of their characteristics. Cell counting, after gradient dilution, use a microscope to count SK-BR-3 cells, and place 30-70 SK-BR-3 cells in step 4.3.1 300μL In the PBMC mixture, cell counting can be performed with a microscope to accurately obtain the number of cells and provide accurate cell concentration for subsequent experiments. The cell concentration can be adjusted by gradient dilution to meet the requirements of cell number in different experimental steps. Mixing SK-BR-3 cells with the PBMC mixture simulates the environment in which tumor cells and normal cells coexist in the body, which is helpful for studying the interaction between tumor cells and host cells. Tumor cell capture requires the use of a pipette to place all the cell mixture in the loading well. The 2000 fully automatic sampler is used to capture and stain tumor cells, which improves the repeatability and accuracy of the experiment and reduces the error of human operation. After the instrument is finished running, the captured cells are counted using a fluorescence microscope. By using a fluorescence microscope to count the captured cells, the cell state can be intuitively observed and analyzed, which is convenient for quantitative analysis and calculation of the capture rate. The effectiveness of the capture method can be evaluated, and data support can be provided for optimizing experimental conditions. The capture rate detection of the tumor cells of the present invention (taking breast cancer SK-BR-3 cells as the target cells) is helpful for studying the biological characteristics and metastasis mechanism of breast cancer cells. The test results show that the capture rate of SK-BR-3 cells by this method is between 65% and 82%, and it has a good cell capture effect. The above steps constitute a complete experimental process, from cell culture to capture The capture rate detection ensures the systematicness and integrity of the experiment. The method is suitable for high-throughput experimental design and can quickly analyze a large number of samples in a short time. By studying the capture and detection of tumor cells, it can provide experimental basis for early diagnosis, efficacy evaluation and prognosis of cancer. By analyzing the characteristics of tumor cells from different patients, it is helpful to develop personalized treatment plans. This method provides an efficient, accurate and repeatable experimental platform for tumor cell research, which helps to promote the development of cancer research and clinical applications. At the same time, the sieve body 1 was used to detect tumor cells in the blood of ten samples. The test results showed that the consistency between the tumor cell detection results and the clinical diagnosis results was 90%. Therefore, the invention can be used to detect tumor cells in the blood, thereby providing tumor patients with a low-invasive, low-cost, fast and accurate detection method.

[0030] The third step is that the material of the screen body 1 is nickel alloy, which has good mechanical properties and corrosion resistance, which makes the screen body 1 have a long service life and stability in biological fluids such as blood. In addition, nickel alloy is often used in the biomedical field to manufacture implants, etc. It has good biocompatibility, reduces interference with blood components and patients' immune responses, and is easy to clean and disinfect, which helps to reuse the screen body 1 and reduce the risk of cross infection. The outer ring diameter of the screen body 1 is 8.8mm and the inner ring diameter is 6.0mm. This design helps to directional capture, that is, only capture cells in a specific area, which can be used to improve the accuracy of capturing tumor cells. The thickness of the screen body 1 is 20μm, which can ensure the uniformity and consistency of filtration, help capture cells of target size, and allow smaller blood cells to pass through. However, the mesh body 1 of this size and design can be easily integrated into automated blood analysis equipment to achieve rapid, high-throughput tumor cell capture and analysis. The mesh body 1 has a pore size of 18 μm and a wire diameter of 8 μm. This design can provide a higher porosity, which helps to improve the filtration efficiency of the mesh body 1, allowing blood cells to pass smoothly while capturing larger tumor cells. By effectively capturing tumor cells in the blood, this mesh body 1 contributes to the early diagnosis and treatment monitoring of cancer. Compared with traditional tissue biopsy, using the mesh body 1 to capture CTCs is a minimally invasive or non-invasive method that is more patient-friendly. In addition, this mesh body 1 can not only be used for clinical diagnosis, but also play a role in cancer biology research, such as studying the heterogeneity and metastasis mechanism of tumor cells.

[0031] The examples of the present invention are given for the purpose of illustration and description, and are not intended to be exhaustive or to limit the invention to the disclosed forms. Many modifications and variations will be apparent to those of ordinary skill in the art. The embodiments are selected and described in order to better illustrate the principles and practical applications of the present invention and to enable those of ordinary skill in the art to understand the present invention and to design various embodiments with various modifications suitable for specific uses.

Claims

1. A screen for capturing tumor cells in human blood, comprising a screen body (1), characterized in that: According to the different sizes of cells, large-sized cells are captured using physical methods, small-sized cells are removed, and the captured cells are stained using immunostaining methods to determine whether they are tumor cells; Among them, a mesh body (1) with a pore size of 13-20μm, a thickness of 10-30μm, and a wire diameter of 5-10μm was used to capture tumor cells, breast cancer SK-BR-3, MCF-7, and MDA-MB-231 cells were used to test the capture rate of the mesh body (1), and colorectal cancer, liver cancer, breast cancer, lung cancer and other cancer types were used to test the clinical consistency of the mesh body (1).

2. A screen for capturing tumor cells in human blood as claimed in claim 1, characterized in that: Draw 4 mL of human peripheral blood into a coagulation tube and store it at 2-8°C for later use.

3. A screen for capturing tumor cells in human blood as claimed in claim 2, characterized in that: Transfer 4 mL of peripheral blood from the anticoagulant tube to a 15 mL centrifuge tube; Among them, 4 mL PBS was added to dilute the blood 1:1 and mixed thoroughly.

4. A screen for capturing tumor cells in human blood as claimed in claim 3, characterized in that: Take 4 mL of lymphocyte separation solution and place it in a new 15 mL centrifuge tube.

5. A screen for capturing tumor cells in human blood as claimed in claim 4, characterized in that: Transfer the diluted blood to a centrifuge tube.

6. A screen for capturing tumor cells in human blood as claimed in claim 5, characterized in that: Centrifuge at room temperature, 2500 rpm, for 20 min.

7. A screen for capturing tumor cells in human blood as claimed in claim 6, characterized in that: After centrifugation, carefully aspirate the plasma layer vertically using a pipette; The PBMC layer was aspirated into a 15 mL centrifuge tube, and 10 mL PBS was added to wash once, and centrifuged at 1500 rpm at room temperature for 5 min.

8. A screen for capturing tumor cells in human blood as claimed in claim 7, characterized in that: After centrifugation, discard the supernatant; Among them, 300 μL PBS was added to resuspend PBMC for later use, and clinical samples were directly loaded onto the machine for testing.

9. A screen for capturing tumor cells in human blood as claimed in claim 8, characterized in that: Use a pipette to place all the cell mixture into the loading well; Among them, a fully automatic sample pipettor is used to capture and stain tumor cells.

10. A screen for capturing tumor cells in human blood as claimed in claim 9, characterized in that: After the instrument run was completed, the captured cells were counted using a fluorescence microscope and the capture rate was calculated.